Hyper IgM syndromes

Current Opinion in Rheumatology

Volumn 15, Issue 4, 2003, Pages 422-429

  Gulino, A Virginia ^a   Notarangelo, Luigi D ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

Author keywords

Class switch recombination; Immunodeficiency; Somatic hypermutation

Indexed keywords

GAMMA INTERFERON; HYPERIMMUNE GLOBULIN; IMMUNOGLOBULIN M;

AUTOIMMUNITY; B LYMPHOCYTE; CARCINOGENESIS; CELL DIFFERENTIATION; CLINICAL FEATURE; DNA REPAIR; GENE MUTATION; GENETIC DISORDER; HUMAN; HYPERIMMUNOGLOBULINEMIA; IMMUNE DEFICIENCY; LYMPHATIC SYSTEM TUMOR; MOLECULAR MECHANICS; PRIORITY JOURNAL; REVIEW; SMALL INTESTINE MUCOSA; SOMATIC HYPERMUTATION; T LYMPHOCYTE; X CHROMOSOME LINKAGE;

HUMANS; HYPERGAMMAGLOBULINEMIA; IMMUNOGLOBULIN CLASS SWITCHING; IMMUNOGLOBULIN M; RECOMBINATION, GENETIC; SYNDROME;

EID: 0038434114     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002281-200307000-00009     Document Type: Review

References (62)

1. Manis JP, Tian M, Alt FW: Mechanism and control of class-switch recombination. Trends Immunol 2002, 23:31-39. This paper is a detailed synthetic review of class switch recombination mechanism. It does not include very recent findings related to the role of UNG.
2. Kinoshita K, Honjo T: Linking class-switch recombination with somatic hypermutation. Nat Rev Mol Cell Biol 2001, 2:493-503.
3. Weill JC, Bertocci B, Faili A, et al,: Ig gene hypermutation: a mechanism is due Adv Immunol 2002, 80:183-202. This review summerizes updated findings concerning somatic hypermutation
4. Durandy A, Honjo T: Human genetic defects in class-switch recombination (hyper-IgM syndromes). Curr Opin Immunol 2001, 13:543-548
5. Durandy A: Hyper-IgM syndromes: a model for studying the regulation of class switch recombination and somatic hypermutation generation. Biochem Soc Trans 2002, 30:815-818. The paper provides an integrated view of available data coming from molecular studies and clinical investigations of patients with hyper IgM syndrome.
6. Kutukculer N, Moratto D, Aydinok Y, et al.: Disseminated Cryptosporidium infection in an infant with hyper-IgM syndrome caused by CD40 deficiency. J Pediatr 2003, 142:99-101. This paper shows that both HIGM1 and HIGM3 are combined immune deficiencies and cause increased susceptibility to severe infections sustained by intracellular pathogens.
7. Ito I, Ishida T, Hashimoto T, et al.: Hyper-IgM sindrome with systemic tuberculosis. Scand J Infect Dis 2002, 34:305-307. This paper shows that both HIGM1 and HIGM3 are combined immune deficiencies and cause increased susceptibility to severe infections sustained by intracellular pathogens.
8. Allen RC, Armitage RJ, Conley ME, et al.: CD40 ligand gene defects responsible for X-linked hyper-IgM syndrome. Science 1993, 259:990-993.
9. Aruffo A, Farrington M, Hollenbaugh D, et al.: The CD40 ligand, gp39, is defective in activated T-cells from patients with X-linked hyper-IgM syndrome. Cell 1993, 72:291-300.
10. DiSanto JP, Bonnefoy JY, Gauchat JF, et al.: CD40 ligand mutations in X-linked immunodeficiency with hyper-IgM. Nature 1993, 361:541-543.
11. Fuleihan R, Ramesh N, Loh R, et al.: Defective expression of the CD40 ligand in X chromosome-linked immunoglobulin deficiency with normal or elevated IgM. Proc Natl Acad Sci U S A 1993, 90:2170-2173.
12. Korthauer U, Graf D, Mages HW, et al.; Defective expression of T-cell CD40 ligand causes X-linked immunodeficiency with hyper IgM. Nature 1993, 361:539-543.
13. Notarangelo LD: and Hayward AR.: X-linked immunodeficiency with hyperIgM (XHIM) Clin Exp Immunol 2000, 120:399-405.
14. Bhushan A, Covey LR: CD40:CD40L interaction in X-linked and non X-linked hyper-IgM syndromes. Immunol Res 2001, 24:311-324.
15. Weller S, Faili A, Garcia C, et al.: CD40-CD40L independent Ig gene hypermutation suggests a second B-cell diversification pathway in humans. Proc Natl Acad Sci U S A 2001, 98:1166-1170.
16. Leone V, Tommasini A, Andotina M, et al.: Elective bone marrow transplantation in a child with X-linked hyper-IgM sindrome presenting with acute respiratory distress syndrome. Bone Marrow Transplant 2002, 30:49-52.
17. Duplantier JE, Seyama K, Day NK, et al.: Immunologic reconstitution following bone marrow transplantation for X-linked hyper IgM syndrome. Clin Immunol 2001, 98:313-318.
18. Ferrari S, Giliani S, Insalaco A, et al.: Mutations of CD40 gene cause an autosomal recessive form of immunodeficiency with hyper IgM. Proc Natl Acad Sci 2001, 98:12614-12619.
19. Minegishi Y, Lavoie A, Cunningham-Rundles C, et al.: Mutations in activation-induced cytidine deaminase in patients with hyper IgM syndrome. Clin Immunol 2000, 97:203-210.
20. Revy P, Muto T, Levy Y, et al.: Activation-induced cytidine deaminase (AID) deficiency causes the autosomal recessive form of the Hyper-IgM syndrome (HIGM2). Cell 2000, 102:565-575.
21. Fargasan S, Muramatsu M, Suzuki K, et al.: Critical roles of activation-induced cytidine deaminase in the homeostasis of gut flora. Science 2002, 298:1424-1427. This article indirectly demonstrates the role of AID in regulating intestinal flora describing the results of experiments conducted on AID-cleficent mice.
22. Zonana J, Elder ME, Schneider LC, et al.: A novel X-linked disorder of immune deficiency and hypohidrotic ectodermal dysplasia is allelic to incontinentia pigmenti and due to mutations in IKK-gamma (NEMO). Am J Hum Genet 2000, 67:1555-1562.
23. Jain A, Ma CA, Liu S, et al.: Specific missense mutations in NEMO result in hyper-IgM syndrome with hypohydrotic ectodermal dysplasia. Nat Immunol 2001, 2:223-228.
24. Doffinger R, Smahi A, Bessia C, et al.: X-linked anhidrotic ectodermal dysplasia with immunodeficiency is caused by impaired NFκB signaling. Nat Genet 2001, 27:277-285.
25. Kim S, La Motte-Mohs RN, Rudolph D, et al.: The role of nuclear factor-{kappa}B essential modulator (NEMO) in B cell development and survival. Proc Natl Acad Sci 2003, 100:1203-1208. The role of NEMO in B-cell development and survival is investigated, and it is shown that NEMO is dispensable for B-cell development but required for B-cell survival.
26. Smahi A, Courtois G, Rabia SH et al.: The NF-kappaB signalling pathway in human diseases: from incontinentia pigmenti to ectodermal dysplasias and immune-deficiency syndromes. Hum Mol Genet 2002, 11:2371-2375. Detailed and exhaustive review of NFκB signaling defects.
27. Orange JS, Brodeur SR, Jain A, et al.: Deficienct natural killer cell cytotoxicity in patients with IKK-gamma/NEMO mutations. J Clin Invest 2002, 109:1501-1509. This paper shows that integrity of IKKγ is crucial not only to allow terminal B-cell differentiation, but also NK cell activity, thus explaining the broad range of susceptibility to infections observed in patients with HIGM-ED.
28. Bancherau J, Bazan F, al Blanchard D: The CD40 antigen and its ligand. Annu Rev Immunol 1994, 12:881.
29. Wolpert KA, Webster ADB, Whittaker SJ: Discoid lupus erythematosus associated with a primary immunodeficiency syndrome showing features of non-X-linked hyper-IgM syndrome. Br Journ Dermatol 1998, 138:1053-1057.
30. Galy AHM, Spits H: CD40 functionally expressed on human thymic epithelium. J Immunol 1992, 149:775.
31. Kumanogoh A, Wang X, Lee I, et al.: Increased T cell autoreactivity in the absence of CD40-CD40Ligand interactions: a role of CD40 in regulatory T cell development. J Immunol 2001, 166:353-360.
32. Foy TM, Page DM, Waldschmidt TJ, et al.: An essential role for gp39, the ligand for CD40, in thymic selection. J Exp Med 1995, 182:1377.
33. Foy TM, Aruffo A, Bajorath J, et al.: Immune regulation by CD40 and its ligand gp39 Annu Rev Immunol 1996, 14:591-617.
34. Mizuta R, Iwai K, Shigeno M, et al.: Molecular visualization of immunoglobulin switch region RNA/DNA complex by atomic force microscope. J Biol Chem 2003, 278:4431-4434.
35. Manis JP, Michaelson JS, Birshtein BK, et al.: Elucidation of a downstream boundary of the 3′ IgH regulatory region. Mol Immunol 2003, 39:753-760.
36. Tian M, Alt FW: Transcription-induced cleavage of immunoglobulin switch regions by nucleotide excision repair nucleases in vitro. J Biol Chem 2000, 275:24163-24172.
37. Petersen S, Casellas R, Reina-San-Martin B, et al.: AID is required to initiate Nbs1/gamma-H2AX focus formation and mutations at sites of class switching. Nature 2001, 6:660-665.
38. Kenter AL: The liaison of isotype class switch and mismatch repair: an illegitimate affair. J Exp Med 1999, 190:307-310.
39. Schrader CE, Edelmann W, Kucherlapati R, et al.: Reduced isotype switching in splenic B-cells from mice deficient in mismatch repair enzymes. J Exp Med 1999, 190:323-330.
40. Papavasiliou FN, Schatz DG: Somatic hypermutation of immunoglobulin genes: merging mechanisms for genetic diversity. Cell 2002, 109:S35-S44.
41. Wiesendanger M, Scharff MD, Edelmann W: Somatic hypermutation, transcription, and DNA mismatch repair. Cell 1998, 94:415-418.
42. Zeng X, Winter DB, Kasmer C, et al.: DNA polymerase eta is an A-T mutator in somatic hypermutation of immunoglobulin variable genes. Nat Immunol 2001, 2:537-541.
43. Zan H, Komori A, Li Z, et al.: The translesion DNA polymerase zeta plays a major role in Ig and bcl-6 somatic hypermutation. Immunity 2001, 14:643-653.
44. Bross L, Fukita Y, McBlane F, et al.: DNA double-strand breaks in immunoglobulin genes undergoing somatic hypermutation. Immunity 2000, 13:589-597.
45. Papavasiliou FN, Schatz DG: Cell-cycle-regulated DNA double stranded breaks in somatic hypermutation of immunoglobulin genes. Nature 2000, 408:216-221.
46. Kim N, Storb U: The role of DNA repair in somatic hypermutation of immunoglobulin genes. J Exp Med 1998, 187:1729-1733.
47. Rogozin IB, Pavlov YI, Bebenek K, et al.: Somatic mutation hotspots correlate with DNA polymerase eta error spectrum. Nat Immunol 2001, 2:530-536.
48. Faili A, Aoufouchi S, Flatter E: Induction of somatic hypermutation in immunoglobulin genes is dependent on DNA polymerase iota. Nature 2002, 419:944-947.
49. Zeng X, Winter D, Kasmer C, et al.: DNA polymerase eta is an A-T mutator in somatic hypermutation of immunoglobulin variable genes. Nat Immunol 2001, 2:537-541.
50. Jacobs H, Bross L: Towards an understanding of somatic hypermutation. Curr Opin Immunol 2001, 13:208-218.
51. Muramatsu M, Sankaranand VS, Anant S, et al.: Specific expression of activation-induced cytidine deaminase (AID), a novel member of the RNA-editing deaminase family in germinal center B-cells. J Biol Chem 1999, 274:18470-18476.
52. Muto T, Muramatsu M, Taniwaki M, et al.: Isolation tissue distribution and chromosomal localization of the human activation-Induced cytidine deaminase (hAID) gene. Genomics 2000, 15:85-88.
53. Muramatsu M, Kinoshita K, Fagarasan S, et al.: Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme. Cell 2000, 102:553-563.
54. Okazaki IM: Kinoshita K., Muramatsu M. et al.: AID enzyme-induced hypermutation in an actively transcribed gene in fibroblasts. Science 2002, 296:20033-20036. See annotation to ref. 55••.
55. Yoshikawa K, Okazaki IM., Eto T, et al.: AID enzyme induces class switch recombination in fibroblasts. Nature 2002, 416:340-345. This paper, along with 54••, provides experimental evidence that AID is the only B-cell specific component of CSR and SHM machinery.
56. Petersen-Mahrt S, Harris R, Neuberger M: AID mutates E. coli suggesting a DNA deamination mechanism for antibody diversification. Nature 2002, 418:99-103. See annotation to ref. 58••.
57. Rada C, Williams G, Nilsen H, et al.: Immunoglobulin isotype switching is inhibited and somatic hypermutation perturbed in UNG-deficient mice. Curr Biol 2002, 12:1748-1755. See annotation to ref, 58••.
58. Di Nola J, Neuberger M: Altering the pathway of immunoglobulin hypermutation by inhibiting uracil-DNA glycosylase. Nature 2002, 419:1-3. This paper (along with 56•• and 57••) reports on the role of base excision-repair, and proposes a unifying model for CSR and SHM, with the demonstration that AID is a DNA-editing enzyme.
59. Zhou T, Zhang J, Carter R, et al.: BLyS and B cell autoimmunity. Curr Dir Autoimmun 2003, 6:21-37.
60. Litinskiy MB: Nardelli B., Hilbert DM. Et al.: DCs induce CD40-independent immunoglobulin class switching through Blys and APRIL. Nat Immunol 2002, 3:822-829. This paper provides demonstration, through in vitro assays, that BLyS and APRIL are able to elicite CD40-independent Ig class switching and plasmacytoid differentiation.
61. Fenton JA, Pratt G, Rawstron AC: Isotype switching and the pathogenesis of multiple myeloma. Hematol Oncol 2002, 20:75-85.
62. Kuppers R, Dalla-Favera R: Mechanisms of chromosomal translocations in B cell lymphomas. Oncogene 2001, 20:5580-5594.